# Combined androgen blockade in androgen receptor-positive salivary gland carcinoma

Source: https://onco.cc/key-papers/paper-fushimi-androgen-deprivation-salivary-duct-ann-oncol-2018/  
OnCo record `paper-fushimi-androgen-deprivation-salivary-duct-ann-oncol-2018` (Key paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Hormone therapy of the kind used in prostate cancer shrank or controlled tumours in most patients with androgen receptor-positive salivary duct carcinoma, a treatment with far less toxicity than chemotherapy.

## Summary

Prospective phase 2 study of 36 patients with androgen receptor-positive locally advanced or metastatic salivary gland carcinoma (predominantly salivary duct carcinoma) treated with leuprorelin and bicalutamide.

Objective response was 41.7 percent with a clinical benefit rate of 75 percent, median progression-free survival 8.8 months and median overall survival 30.5 months, and toxicity was mild.

## Fields

- Kind: Key paper
- Last checked: 2026-09-17
- Journal: Annals of Oncology
- Year: 2018
- DOI: 10.1093/annonc/mdx771
- Authors: Fushimi C, Tada Y, Takahashi H, et al.
- Findings: Objective response 41.7 percent; clinical benefit 75 percent.; Median progression-free survival 8.8 months; median overall survival 30.5 months.
- What it means: Androgen receptor testing and androgen deprivation therapy are now standard options for salivary duct carcinoma, often before chemotherapy in slowly progressing disease.
- Caveats: Small single-arm trial; a subsequent randomised comparison with chemotherapy showed similar efficacy with less toxicity.

## Sources

- Ann Oncol 2018: https://doi.org/10.1093/annonc/mdx771
- PubMed: https://pubmed.ncbi.nlm.nih.gov/29211833/

## Connected records

- cancers: [Salivary duct carcinoma](https://onco.cc/cancers/salivary-duct-carcinoma/)
- journals: [Annals of Oncology](https://onco.cc/journals/annals-of-oncology/)

---
JSON: https://onco.cc/api/v1/entities/paper-fushimi-androgen-deprivation-salivary-duct-ann-oncol-2018.json